CD4 and CD8 T-Lymphocyte Recognition of Prostate Specific Antigen in Granulomatous Prostatitis

Journal of Immunotherapy

Volumn 27, Issue 2, 2004, Pages 136-146

  Klyushnenkova, Elena N ^a,b   Ponniah, Sathibalan ^a   Rodriguez, Alejandro ^a   Kodak, James ^a   Mann, Dean L ^a   Langerman, Alexander ^c   Nishimura, Michael I ^c   Alexander, Richard B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Granulomatous prostatitis; Immunotherapy; Prostate cancer; Prostate specific antigen (PSA); T lymphocytes

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA B ANTIGEN; HLA DR ANTIGEN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ARTICLE; B LYMPHOCYTE; BIOENGINEERING; CANCER CELL; CANCER IMMUNOTHERAPY; CELL LINE; CELL SURFACE; CELLULAR IMMUNITY; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; GRANULOMATOSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IRRADIATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PURIFICATION; T LYMPHOCYTE; VACCINIA VIRUS;

EID: 1442360438     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200403000-00007     Document Type: Article

References (39)

1. Papsidero LD, Kuriyama M, Wang MC, et al. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst. 1981;66:37-42.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18:175-182.
3. Boon T, Coulie PG, Van den EB. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-268.
4. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor markers for adenocarcinoma of prostate. J. Urol. 1991;145:907-923.
5. Meidenbauer N, Harris DT, Spitler LE, et al. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 2000;43:88-100.
6. Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine [published erratum appears in Oncogene 1999;18:2411.]. Oncogene. 1998;17:3125-3135.
7. Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine [published erratum appears in Oncogene 1999;18:2411.]. Oncogene. 1998;17:3125-3135.
8. Heiser A, Dahm P, Yancey R, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol. 2000;164:5508-5514.
9. Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol. 1998;161:3186-3194.
10. Alexander RB, Brady F, Leffell MS, et al. Specific T cell recognition of peptides derived from prostate specific antigen in patients with prostatic cancer. Urology. 1998;51:150-157.
11. Liu KJ, Chatta GS, Twardzik DR, et al. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol. 1997;159:472-480.
12. Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997;159:3113-3117.
13. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167:7150-7156.
14. Alexander RB, Trissel D. Chronic prostatitis: Results of an internet survey. Urology. 1996;48:568-574.
15. Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: Evidence of T cell reactivity with normal prostatic proteins. Urology. 1997;50:893-899.
16. Alexander RB, Ponniah S, Hasday J, et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology. 1998;52:744-749.
17. Nadler RB, Koch AE, Calhoun EA, et al. 1L-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol. 2000;164:214-218.
18. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000;44:49-54.
19. Zhang WM, Leinonen J, Kalkkinen N, et al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 1995;41:1567-1573.
20. Nutman, TB. Long-term and immortalized human cell lines and clonees. In: Coligan JE, et al. eds. Current Protocols in Immunology. 1991;7.19.1-7.19.6.
21. Berlyn KA, Ponniah S, Stass SA, et al. Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. J Biotechnol. 1999;73:155-179.
22. Alexander RB, Fitzgerald EB, Mixon A, et al. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J Immunother. 1995;17:39-46.
23. Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer. 1995;63:231-237.
24. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate. 1988;12:29-38.
25. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs. Nature. 1998;392:86-89.
26. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638.
27. + T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. Int J Cancer. 2002;98:57-62.
28. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA. 1994;91:2105-2109.
29. Xue BH, Zhang Y, Sosman JA, et al. Induction of human cytotoxic T lymphocytes specific for prostate- specific antigen. Prostate. 1997;30:73-78.
30. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89:293-300.
31. Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998;114:166-172.
32. Matsuo H, Batocchi A, Hawke S, et al. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol. 1995;155:3683-3692.
33. True LD, Berger RE, Rothman I, et al. Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol. 1999;162:2014-2018.
34. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol. 1979;121:755-760.
35. Zhang W, Sesterhenn IA, Connelly RR, et al. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131-136.
36. Dhundee J, Maciver AG. An immunohistological study of granulomatous prostatitis. Histopathology. 1991;18:435-441.
37. Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol. 1987;138:320-323.
38. Allcock RJ, de la Concha EG, Femandez-Arquero M, et al. Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster. Hum Immunol. 1999;60:1266-1273.
39. Madigand M, Oger JJ, Fauchet R, et al. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci. 1982;53:519-529.